Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CRL [NYSE]
Charles River Laboratories International, Inc.
Healthcare | Diagnostics & Research | USA
statements
IndexS&P 500 P/E53.44 EPS (ttm)7.75 Insider Own0.90% Shs Outstand50.30M Perf Week1.53%
Market Cap20.98B Forward P/E35.96 EPS next Y11.51 Insider Trans-13.88% Shs Float49.67M Perf Month-6.00%
Income396.10M PEG3.82 EPS next Q2.58 Inst Own97.30% Short Float1.27% Perf Quarter7.40%
Sales3.27B P/S6.41 EPS this Y41.90% Inst Trans-0.06% Short Ratio1.90 Perf Half Y28.43%
Book/sh46.09 P/B8.98 EPS next Y11.92% ROA6.80% Target Price448.00 Perf Year72.30%
Cash/sh4.42 P/C93.67 EPS next 5Y14.00% ROE18.60% 52W Range219.79 - 460.21 Perf YTD65.70%
Dividend- P/FCF43.35 EPS past 5Y17.90% ROI8.60% 52W High-10.04% Beta1.12
Dividend %- Quick Ratio1.20 Sales past 5Y16.50% Gross Margin37.90% 52W Low88.37% ATR11.35
Employees18400 Current Ratio1.40 Sales Q/Q34.00% Oper. Margin16.00% RSI (14)47.60 Volatility2.15% 2.81%
OptionableYes Debt/Eq1.18 EPS Q/Q28.40% Profit Margin12.10% Rel Volume0.74 Prev Close403.54
ShortableYes LT Debt/Eq1.18 EarningsNov 03 BMO Payout0.00% Avg Volume332.38K Price414.01
Recom1.80 SMA20-1.39% SMA50-2.77% SMA20019.48% Volume246,118 Change2.59%
Aug-05-21Resumed Credit Suisse Neutral $385
Dec-16-20Downgrade Citigroup Buy → Neutral $270 → $250
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Oct-18-19Downgrade BofA/Merrill Buy → Neutral $150
Jun-10-19Initiated SVB Leerink Outperform $155
Apr-30-19Resumed Evercore ISI Outperform $160
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Oct-18-21 09:07AM  
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
Business Wire
Oct-14-21 08:58AM  
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
Simply Wall St.
Oct-13-21 04:30PM  
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call
Business Wire
Oct-12-21 07:00PM  
Charles River Laboratories Announces Two Divestitures
Business Wire
Oct-04-21 11:46AM  
Hedge Funds Keep Buying Charles River Laboratories International Inc. (CRL)
Insider Monkey
Oct-01-21 01:13PM  
Heres What Makes Charles River Laboratories (CRL) A Great Investment
Insider Monkey
Sep-20-21 08:00AM  
Charles River Launches First Annual Healthcare Collaboration Report
Business Wire
Sep-14-21 09:44AM  
Here's Why You Should Invest in Charles River (CRL) Now
Zacks
Sep-11-21 10:34AM  
Here's Why I Think Charles River Laboratories International (NYSE:CRL) Is An Interesting Stock
Simply Wall St.
Sep-07-21 08:00AM  
Charles River Laboratories to Participate in September Investor Conferences
Business Wire
Sep-03-21 11:31AM  
Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?
Zacks
Aug-21-21 07:30AM  
You Won't Believe the Risk This Healthcare Company Faces
Motley Fool
Aug-20-21 11:49AM  
A surprising key to making sure vaccines including for COVID-19 are safe? The blue blood of horseshoe crabs
MarketWatch
Aug-19-21 09:27AM  
Charles River (CRL) at a 52-Week High: What's Driving It?
Zacks
Aug-12-21 06:58AM  
Charles River Laboratories International, Inc. (NYSE:CRL) Has A ROE Of 17%
Simply Wall St.
Aug-11-21 11:40AM  
MODV or CRL: Which Is the Better Value Stock Right Now?
Zacks
Aug-04-21 04:30PM  
Charles River Laboratories International, inc (CRL) Q2 2021 Earnings Call Transcript
Motley Fool
09:00AM  
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
Zacks
08:25AM  
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Zacks
07:00AM  
Charles River Laboratories Announces Second-Quarter 2021 Results
Business Wire
Jul-29-21 11:54AM  
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
Zacks
Jul-28-21 03:03PM  
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Zacks
Jul-13-21 10:06AM  
Charles River (CRL) at a 52-Week High: What's Driving It?
Zacks
08:30AM  
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
Business Wire
Jul-08-21 11:10AM  
10 Top-Ranked Stocks Powering S&P 500 ETF
Zacks
Jul-06-21 02:31AM  
Charles River Laboratories International, Inc.'s (NYSE:CRL) Intrinsic Value Is Potentially 23% Below Its Share Price
Simply Wall St.
Jul-02-21 07:45PM  
Nine Top Growth Stocks Rise 3% Or More, Accenture Joins Watchlist; Will Amedisys Usher An Early Entry?
Investor's Business Daily
Jun-30-21 09:46AM  
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
Zacks
Jun-29-21 07:00AM  
Charles River Laboratories Completes Acquisition of Vigene Biosciences
Business Wire
Jun-23-21 10:44AM  
Here is What Hedge Funds Think About Charles River Laboratories International Inc. (CRL)
Insider Monkey
Jun-22-21 12:00PM  
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Zacks
Jun-10-21 08:00AM  
Charles River's Jim Foster Beat The Trauma Of Being CEO
Investor's Business Daily
Jun-07-21 08:00AM  
Duke Energy Sustainable Solutions will build its largest solar project to date: 250-MW Pisgah Ridge Solar in Texas
PR Newswire
08:00AM  
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
Business Wire
Jun-06-21 03:55AM  
Is Charles River Laboratories International's (NYSE:CRL) 298% Share Price Increase Well Justified?
Simply Wall St.
May-28-21 08:00AM  
Charles River Laboratories to Participate in June Investor Conferences
Business Wire
May-26-21 04:30PM  
Charles River Laboratories to Host Virtual Investor Day
Business Wire
08:05AM  
S&P 500 Stock Diagnoses Breakout After Buying Spree, 455% Growth
Investor's Business Daily
May-25-21 01:15PM  
IBD 50 Stocks To Watch: Clinical Research Leader Charles River Labs In Buy Range After Strong Rebound
Investor's Business Daily
May-17-21 01:16PM  
Charles River Acquires Viral Vector Player For $350M
Benzinga
07:00AM  
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
Business Wire
May-10-21 06:37PM  
Charles River Laboratories International Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR Newswire
04:54PM  
Was The Smart Money Right About Piling Into Charles River Laboratories (CRL)?
Insider Monkey
May-07-21 03:18AM  
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Simply Wall St.
May-05-21 07:00PM  
Charles River Labs Joins Elite List Of Stocks With 95-Plus Composite Rating
Investor's Business Daily
May-04-21 03:31PM  
Charles River Laboratories International Inc (CRL) Q1 2021 Earnings Call Transcript
Motley Fool
08:35AM  
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
Zacks
07:00AM  
Charles River Laboratories Announces First-Quarter 2021 Results
Business Wire
Apr-23-21 04:25PM  
Three Scorching Medical Stocks To Watch, Including One Near A Buy Point
Investor's Business Daily
Apr-16-21 10:45AM  
Charles River Labs International Shows Rising Relative Strength
Investor's Business Daily
Apr-13-21 08:30AM  
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
Business Wire
Apr-06-21 04:43PM  
Stocks Close Lower After S&P 500 Hits New High; These Stocks Break Out
Investor's Business Daily
08:00AM  
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Business Wire
Apr-04-21 05:16AM  
I Ran A Stock Scan For Earnings Growth And Charles River Laboratories International (NYSE:CRL) Passed With Ease
Simply Wall St.
Mar-31-21 07:00AM  
Charles River Laboratories Acquires Retrogenix
Business Wire
Mar-29-21 04:19PM  
Is CRL Stock A Buy or Sell?
Insider Monkey
04:15PM  
Charles River Laboratories Completes the Acquisition of Cognate BioServices
Business Wire
Mar-23-21 04:30PM  
Charles River Laboratories Announces Closing of Senior Notes Offering
Business Wire
Mar-09-21 08:00AM  
Charles River Laboratories Prices $1 Billion of Senior Notes
Business Wire
Mar-08-21 11:11AM  
Charles River Laboratories Int'l, Inc. -- Moody's assigns Ba2 ratings to Charles River's new senior unsecured notes
Moody's
09:15AM  
Charles River Laboratories Announces Planned Offering of $1 Billion of Senior Notes
Business Wire
08:30AM  
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Business Wire
Mar-05-21 04:51AM  
Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market Following Fundamentals?
Simply Wall St.
Feb-25-21 08:00AM  
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
Business Wire
Feb-24-21 05:20AM  
Look for the Rally in Charles River Labs to Continue
TheStreet.com
Feb-18-21 01:15PM  
Charles River Labs International Shows Improved Relative Strength; Still Shy Of Benchmark
Investor's Business Daily
08:52AM  
A Look Into Charles River's Debt
Benzinga
Feb-17-21 04:00PM  
Charles River Laboratories International Inc (CRL) Q4 2020 Earnings Call Transcript
Motley Fool
07:35AM  
Charles River: Q4 Earnings Insights
Benzinga
07:08AM  
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
Business Wire
07:06AM  
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
Business Wire
Feb-10-21 12:31PM  
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jan-29-21 12:10PM  
Why Charles River (CRL) Could Beat Earnings Estimates Again
Zacks
Jan-28-21 08:00AM  
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
Business Wire
Jan-21-21 11:57PM  
Estimating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Simply Wall St.
Jan-20-21 08:30AM  
Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call
Business Wire
Jan-15-21 12:57PM  
Ariel Investments, Still Hopeful for Charles River Lab (CRL) to Continue Positive Momentum
Insider Monkey
Jan-14-21 08:00AM  
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
Business Wire
Jan-11-21 08:00AM  
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Business Wire
Jan-06-21 04:03PM  
Charles River Labs Eyes 'SuperHuman' Gains As Breakout Nears
Investor's Business Daily
Jan-04-21 07:00AM  
Charles River Laboratories Acquires Distributed Bio
Business Wire
Dec-25-20 02:44PM  
Is CRL A Good Stock To Buy Now?
Insider Monkey
Dec-23-20 12:34AM  
If You Had Bought Charles River Laboratories International (NYSE:CRL) Stock Five Years Ago, You Could Pocket A 214% Gain Today
Simply Wall St.
Dec-21-20 01:42AM  
Toshiba Corporation -- Moody's withdraws Toshiba's B1 and Not Prime ratings for business reasons
Moody's
Dec-16-20 12:16PM  
Is Charles River Laboratories (CRL) a Smart Long-term Buy?
Insider Monkey
Dec-09-20 08:00AM  
Charles River Delivers Industry-First Deciphex Patholytix Digital Pathology Peer Review for GLP Studies
Business Wire
Nov-27-20 12:43AM  
Is Now An Opportune Moment To Examine Charles River Laboratories International, Inc. (NYSE:CRL)?
Simply Wall St.
Nov-20-20 03:07PM  
Charles River Laboratories Int'l, Inc. -- Moody's upgrades Charles River's CFR to Ba1; outlook stable
Moody's
Nov-19-20 12:45PM  
Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why
Zacks
Nov-12-20 08:00AM  
Charles River and PathoQuest Strengthen Strategic Partnership
Business Wire
Nov-09-20 08:30AM  
Charles River Laboratories to Present at Upcoming Investor Conferences
Business Wire -5.35%
Nov-05-20 09:15AM  
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?
Zacks
Nov-03-20 12:45PM  
3 Reasons Growth Investors Will Love Charles River (CRL)
Zacks
Nov-01-20 08:20AM  
Earnings Beat: Charles River Laboratories International, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St.
Oct-30-20 04:31AM  
Charles River Laboratories International Inc (CRL) Q3 2020 Earnings Call Transcript
Motley Fool
Oct-29-20 09:00PM  
Toshiba Honored with Five Accolades at GOOD DESIGN AWARD 2020
PR Newswire
07:00AM  
Charles River Laboratories Announces Third-Quarter 2020 Results
Business Wire
Oct-28-20 12:26PM  
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
Zacks
Oct-27-20 06:03PM  
Were Hedge Funds Right About Crowding Into Charles River Laboratories (CRL)?
Insider Monkey
Oct-26-20 06:53AM  
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Simply Wall St.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Girshick BirgitCorporate Executive VPSep 14Sale439.902,3441,031,12627,602Sep 15 11:11 AM
Girshick BirgitCorporate Executive VPSep 13Sale442.198135,81729,946Sep 15 11:11 AM
MASSARO GEORGEDirectorAug 31Option Exercise164.242,539417,0057,394Sep 01 02:29 PM
MASSARO GEORGEDirectorAug 31Sale442.482,5391,123,4574,855Sep 01 02:29 PM
Creamer Victoria LEVP & Chief People OfficerAug 16Option Exercise145.346,9171,005,33013,303Aug 17 03:01 PM
Creamer Victoria LEVP & Chief People OfficerAug 16Sale415.246,9172,872,2366,386Aug 17 03:01 PM
Smith David RossCorporate Executive VP & CFOAug 09Sale407.401,750712,95414,425Aug 10 11:58 AM
Kochevar Deborah TurnerDirectorAug 06Option Exercise164.242,539417,0059,622Aug 10 11:47 AM
Barbo William DCorporate Executive VP & CCOAug 06Option Exercise136.617,4721,020,71716,758Aug 10 11:52 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopAug 06Sale402.213,7001,488,1758,462Aug 10 11:56 AM
Barbo William DCorporate Executive VP & CCOAug 06Sale402.8212,3874,989,7524,371Aug 10 11:52 AM
Kochevar Deborah TurnerDirectorAug 06Sale406.433,5261,433,0716,096Aug 10 11:47 AM
FOSTER JAMES CChairman, President and CEOAug 06Sale401.7910,0004,017,867202,299Aug 10 11:42 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 04Option Exercise144.951,527221,3395,757Jun 07 06:23 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 04Sale335.241,527511,9064,230Jun 07 06:23 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 03Option Exercise101.4780081,1755,030Jun 04 09:34 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 03Sale329.76800263,8094,230Jun 04 09:34 AM
FOSTER JAMES CChairman, President and CEOJun 01Option Exercise179.669,5771,720,604224,376Jun 03 12:48 PM
FOSTER JAMES CChairman, President and CEOJun 01Sale332.239,5773,181,749214,799Jun 03 12:48 PM
MASSARO GEORGEDirectorMay 11Sale320.06371118,7435,355May 12 04:45 PM
FOSTER JAMES CChairman, President and CEOMay 07Sale343.177,5002,573,770216,072May 10 05:13 PM
MASSARO GEORGEDirectorMay 06Sale336.963,3701,135,5615,371May 07 01:23 PM
Smith David RossCorporate Executive VP & CFOMay 04Option Exercise144.673,305478,13418,167May 06 01:21 PM
Smith David RossCorporate Executive VP & CFOMay 04Sale340.013,3051,123,71814,862May 06 01:21 PM
Smith David RossCorporate Executive VP & CFOApr 22Option Exercise109.343,845420,41218,707Apr 26 01:09 PM
Smith David RossCorporate Executive VP & CFOApr 22Sale330.003,8451,268,85014,862Apr 26 01:09 PM
Smith David RossCorporate Executive VP & CFOApr 15Sale320.002,000640,00014,862Apr 16 03:23 PM
Girshick BirgitCorporate Executive VPApr 06Option Exercise113.7918,3112,083,69535,469Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 06Sale302.6118,3115,541,10429,060Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 05Option Exercise88.0599987,96230,059Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 05Sale298.00999297,70229,060Apr 07 11:26 AM
Barbo William DCorporate Executive VP & CCOMar 01Option Exercise88.053,493307,5597,311Mar 02 04:37 PM
Smith David RossCorporate Executive VP & CFOMar 01Option Exercise88.054,366384,42621,228Mar 02 04:39 PM
MILNE GEORGE M JRDirectorMar 01Option Exercise52.293,530184,58431,947Mar 02 04:47 PM
Smith David RossCorporate Executive VP & CFOMar 01Sale290.124,3661,266,64716,862Mar 02 04:39 PM
Barbo William DCorporate Executive VP & CCOMar 01Sale290.431,157336,02816,975Mar 02 04:37 PM
Barbo William DCorporate Executive VP & CCOMar 01Sale290.103,4931,013,3123,818Mar 02 04:37 PM
MILNE GEORGE M JRDirectorMar 01Sale290.013,5301,023,73028,417Mar 02 04:47 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 25Option Exercise88.052,750242,13819,996Feb 26 04:51 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 25Sale281.708,7352,460,61511,261Feb 26 04:51 PM
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise88.0524,0092,113,992245,160Feb 25 04:23 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale284.7524,0096,836,607221,151Feb 25 04:23 PM
FOSTER JAMES CChairman, President and CEOFeb 23Option Exercise109.3420,2952,219,055243,656Feb 24 11:10 AM
CHUBB STEPHEN DDirectorFeb 23Option Exercise52.293,530184,58441,187Feb 24 11:02 AM
CHUBB STEPHEN DDirectorFeb 23Sale281.66658185,33040,529Feb 24 11:02 AM
FOSTER JAMES CChairman, President and CEOFeb 23Sale279.8020,2955,678,578223,361Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 22Option Exercise144.6717,4362,522,466244,605Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 22Sale282.9817,4364,934,118227,169Feb 24 11:10 AM
Girshick BirgitCorporate Executive VPFeb 19Option Exercise73.701,675123,44831,680Feb 23 11:41 AM
Girshick BirgitCorporate Executive VPFeb 19Sale293.921,675492,31130,005Feb 23 11:41 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerFeb 19Sale290.99410119,3054,198Feb 23 11:32 AM
Smith David RossCorporate Executive VP & CFOFeb 19Sale290.638,6562,515,6860Feb 23 11:16 AM
FOSTER JAMES CChairman, President and CEOFeb 11Sale285.0230,0008,550,556227,169Feb 16 11:58 AM
Smith David RossCorporate Executive VP & CFOJan 04Sale248.765,0001,243,78815,767Jan 05 05:21 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Option Exercise123.736,739833,84118,095Nov 05 11:46 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Sale250.286,7391,686,62711,356Nov 05 11:46 AM
Barbo William DCorporate Executive VP & CCONov 03Sale236.292,150508,0159,821Nov 05 03:51 PM
WALLMAN RICHARD FDirectorNov 02Buy233.246,0501,411,1046,050Nov 03 01:21 PM
WALLMAN RICHARD FDirectorNov 02Buy232.961,150267,90231,715Nov 03 01:21 PM
FOSTER JAMES CChairman, President and CEONov 02Sale232.3822,0005,112,267186,777Nov 03 04:05 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.